PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
August 1, 2025

Inhibiting the alarmin-driven hematopoiesis-stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis.

View Full Paper
Ask AI
Bookmark
Share

Authors

HGHélène F.E. GleitzWellcome Centre for Cell-Matrix ResearchSFStijn FuchsErasmus MCISInge SnoerenErasmus MC

Discussion

Loading...

Member takes

Overview

Observational analysis shows tasquinimod reduced inflammation and fibrosis in primary myelofibrosis, indicating a therapeutic potential.

Key Points

  • Inhibiting hematopoiesis-stromal cell interactions significantly decreases bone marrow fibrosis.
  • Tasquinimod treatment reduced S100A8 levels and improved the MPN phenotype in a JAK2V617F model.
  • Coculture experiments demonstrated the impact of JAK2V617F cells on mesenchymal stromal cells, highlighting inflammation.
  • Targeting inflammatory signaling may provide new therapeutic strategies for managing primary myelofibrosis.

Cite This Study

Gleitz et al. (2025) studied this question.

synapsesocial.com/papers/68af4754ad7bf08b1ead3cf2https://doi.org/10.1002/hem3.70179
View Full Paper
Ask AI
Bookmark
Share